The link between the IGF1/IGF1R axis and brain pathologies, particularly AD, has been the topic of significant interest in recent years, with several studies advocating that the modulation of the IGF1R can alter AD-related pathological features, the deposition of amyloid β-peptide (Aβ) and hyperphosphorylated Tau protein. The gene discussed is MAPT; the disease is Alzheimer disease.